Caroline Kant

EspeRare is accelerating the cost-effective development of unexplored treatments for rare diseases acting as a philanthropic, knowledge, and technical broker between patients, pharmaceutical industry and regulators to bring treatments for these underserved patients. With its pharma partner: Merck Serono, the foundation is enabling a dormant drug, with a high therapeutic potential for children affected by a rare incurable disease, to be developed.